Jeremy S. Abramson, MD
The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response (CR) rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma (NHL), according to findings from the multicenter, phase I TRANSCEND study presented at the 2016 ASH Annual Meeting.
Patients had received a median of 4 prior therapies (range, 1-8), and a quarter had received ≥5 prior lines of therapy. Overall, 57% of patients received stem cell transplants, which were allogeneic (14%) and autologous (46%).
In 27 efficacy evaluable patients treated across doses, the ORR was 78%, with a CR rate of 52%. Those with chemorefractory DLBCL (n = 16) had an ORR of 75%, which included a CR rate of 56%. Overall, 2 patients had double-hit, 3 had triple-hit, and 4 had double-expresser DLBCL. Within this group of 9 patients with aggressive subtypes, there were 7 CRs and 2 PRs.
... to read the full story